BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 21532533)

  • 1. Comparison of the VASP assay and platelet aggregometry in the evaluation of platelet P2Y12 receptor blockade.
    Kuliczkowski W; Rychlik B; Chiżyński K; Watała C; Golański J
    Pol Arch Med Wewn; 2011 Apr; 121(4):115-21. PubMed ID: 21532533
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of conventional aggregometry with VASP for monitoring P2Y12-specific platelet inhibition.
    Aradi D; Magyarlaki T; Tokés-Füzesi M; Rideg O; Vorobcsuk A; Komócsi A
    Platelets; 2010; 21(7):563-70. PubMed ID: 20642320
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of VASP-phosphorylation assay to light-transmission aggregometry in assessing inhibition of the platelet ADP P2Y12 receptor.
    Pampuch A; Cerletti C; de Gaetano G
    Thromb Haemost; 2006 Dec; 96(6):767-73. PubMed ID: 17139371
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relation between the vasodilator-stimulated phosphoprotein phosphorylation assay and light transmittance aggregometry in East Asian patients after high-dose clopidogrel loading.
    Kim IS; Jeong YH; Tantry US; Park Y; Lee DH; Bliden KP; Koh JS; Park JR; Jang JS; Hwang SJ; Koh EH; Kwak CH; Hwang JY; Kim S; Gurbel PA
    Am Heart J; 2013 Jul; 166(1):95-103. PubMed ID: 23816027
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison of the antiplatelet effects of prasugrel and high-dose clopidogrel as assessed by VASP-phosphorylation and light transmission aggregometry.
    Jakubowski JA; Payne CD; Li YG; Farid NA; Brandt JT; Small DS; Salazar DE; Winters KJ
    Thromb Haemost; 2008 Jan; 99(1):215-22. PubMed ID: 18217157
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiple electrode aggregometry and vasodilator stimulated phosphoprotein-phosphorylation assay in clinical routine for prediction of postprocedural major adverse cardiovascular events.
    Freynhofer MK; Brozovic I; Bruno V; Farhan S; Vogel B; Jakl G; Willheim M; Hübl W; Wojta J; Huber K
    Thromb Haemost; 2011 Aug; 106(2):230-9. PubMed ID: 21614416
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Platelet responsiveness to clopidogrel in patients with coronary syndrome. Comparison of platelet aggregation induced by ADP and flow cytometric analysis of intraplatelet VASP phosphorylation].
    Morel O; Viellard C; Faure A; Jesel L; Ohlmann P; Desprez D; Chauvin M; Roul G; Grunebaum L; Bareiss P
    Ann Cardiol Angeiol (Paris); 2007 Jan; 56(1):21-9. PubMed ID: 17343035
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of four methods to assess high-on platelet reactivity under P2Y12 receptor inhibitor.
    Mingant F; Didier R; Gilard M; Martin F; Nicol PP; Ugo V; Lippert E; Galinat H
    Platelets; 2018 May; 29(3):257-264. PubMed ID: 29580115
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of a new P2Y12 receptor specific platelet aggregation test with other laboratory methods in stroke patients on clopidogrel monotherapy.
    Bagoly Z; Sarkady F; Magyar T; Kappelmayer J; Pongrácz E; Csiba L; Muszbek L
    PLoS One; 2013; 8(7):e69417. PubMed ID: 23844259
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The new INNOVANCE® PFA P2Y cartridge is sensitive to the detection of the P2Y₁₂ receptor inhibition.
    Koessler J; Kobsar AL; Rajkovic MS; Schafer A; Flierl U; Pfoertsch S; Bauersachs J; Steigerwald U; Rechner AR; Walter U
    Platelets; 2011; 22(1):20-7. PubMed ID: 20873965
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Poor agreement between light transmission aggregometry, Verify Now P2Y₁₂ and vasodilatator-stimulated phosphoprotein for clopidogrel low-response assessment: a potential explanation of negative results of recent randomized trials.
    Lemesle G; Landel JB; Bauters A; Delhaye C; Bonello L; Sudre A; Susen S; Bauters C; Lablanche JM
    Platelets; 2014; 25(7):499-505. PubMed ID: 24176022
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential sensitivity and kinetics of response of different ex vivo tests monitoring functional variability of platelet response to clopidogrel.
    Bal Dit Sollier C; Berge N; Boval B; Dubar M; Drouet L
    Thromb Haemost; 2010 Sep; 104(3):571-81. PubMed ID: 20664906
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of a new ELISA assay with the flow cytometric assay for platelet vasodilator-associated stimulated phosphoprotein (VASP) phosphorylation in whole blood to assess P2Y(12) inhibition.
    Jakubowski JA; Bourguet N; Boulay-Moine D; Sugidachi A; Yamaguchi S; Barragan P; Zhou C; Moulard M
    Thromb Haemost; 2012 Feb; 107(2):388-95. PubMed ID: 22186965
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of platelet response to clopidogrel with multiple electrode aggregometry, the VerifyNow P2Y12 analyzer and platelet Vasodilator-Stimulated Phosphoprotein flow cytometry.
    von Beckerath N; Sibbing D; Jawansky S; Braun S; Morath T; Vogt W; Schömig A; Kastrati A
    Blood Coagul Fibrinolysis; 2010 Jan; 21(1):46-52. PubMed ID: 19823079
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The influencing factors for clopidogrel-mediated platelet inhibition are assay-dependent.
    Gremmel T; Steiner S; Seidinger D; Koppensteiner R; Panzer S; Kopp CW
    Thromb Res; 2011 Oct; 128(4):352-7. PubMed ID: 21621250
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation between light transmission aggregometry, VerifyNow P2Y12, and VASP-P platelet reactivity assays following percutaneous coronary intervention.
    Gaglia MA; Torguson R; Pakala R; Xue Z; Sardi G; Suddath WO; Kent KM; Satler LF; Pichard AD; Waksman R
    J Interv Cardiol; 2011 Dec; 24(6):529-34. PubMed ID: 21919956
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship between pharmacokinetics and pharmacodynamics of clopidogrel in patients undergoing percutaneous coronary intervention: comparison between vasodilator-stimulated phosphoprotein phosphorylation assay and multiple electrode aggregometry.
    Danese E; Fava C; Beltrame F; Tavella D; Calabria S; Benati M; Gelati M; Gottardo R; Tagliaro F; Guidi GC; Cattaneo M; Minuz P
    J Thromb Haemost; 2016 Feb; 14(2):282-93. PubMed ID: 26576037
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases.
    Aleil B; Ravanat C; Cazenave JP; Rochoux G; Heitz A; Gachet C
    J Thromb Haemost; 2005 Jan; 3(1):85-92. PubMed ID: 15634270
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of a new ELISA-based with the flow cytometric assay for vasodilator-associated stimulated phosphoprotein phosphorylation to assess P2Y12 -inhibition after ticagrelor intake.
    Hobl EL; Jilma B; Derhaschnig U; Schoergenhofer C; Schwameis M; Jilma-Stohlawetz P
    Cytometry B Clin Cytom; 2015; 88(6):385-8. PubMed ID: 24038908
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacodynamic effects of cangrelor on platelet P2Y12 receptor-mediated signaling in prasugrel-treated patients.
    Rollini F; Franchi F; Tello-Montoliu A; Patel R; Darlington A; Ferreiro JL; Cho JR; Muñiz-Lozano A; Desai B; Zenni MM; Guzman LA; Bass TA; Angiolillo DJ
    JACC Cardiovasc Interv; 2014 Apr; 7(4):426-34. PubMed ID: 24630878
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.